Candida auris for FRCPath Medical Microbiology Part 2: Diagnosis, Treatment, Outbreaks and Exam Tips
A yeast isolate from a blood culture is not usually treated as an infection control emergency. This one can be. Candida auris matters because it combines three features that examiners love and hospitals fear: difficult identification, antifungal resistance, and an ability to spread in healthcare settings.
For FRCPath Medical Microbiology Part 2, this organism sits at the intersection of bench microbiology, clinical advice, infection prevention and outbreak management. A strong answer should move easily from “what is the isolate?” to “what does the ward need to do by the end of the day?”
This post covers the exam-relevant facts, the practical laboratory pathway, treatment principles, and how to frame an outbreak answer in a viva or written scenario.
Why this organism is significant in healthcare
The organism is an emerging multidrug-resistant yeast associated with healthcare-associated transmission. It was first recognised as a distinct species in the modern microbiology era after isolates were recovered from ear specimens, but its importance now comes mainly from invasive disease and outbreaks.
Several features make it significant.
It can cause candidaemia and other invasive infections, especially in critically ill patients. Mortality in reported invasive cases is high, although deaths usually reflect both infection and severe underlying illness.
It can persist on skin and in the environment. This differs from the way many candidates think about Candida species as mainly endogenous flora. For this organism, healthcare transmission through contact with patients, equipment and contaminated surfaces is central.
It is often resistant to fluconazole. Some isolates show resistance to amphotericin B, and a smaller but important proportion are resistant to echinocandins. This creates real treatment pressure because echinocandins are usually first-line therapy for invasive disease.
It may be misidentified by older or incomplete commercial identification systems. This is a common exam trap. If the laboratory reports an unusual Candida in a high-risk clinical setting, the correct next step may be confirmatory identification, not quiet acceptance of the result.
It has caused outbreaks across acute hospitals, long-term care facilities and high-dependency settings. Public health agencies including the UK Health Security Agency, the US Centers for Disease Control and Prevention, and the World Health Organization have all highlighted it as a priority fungal pathogen.
For exams, the key point is simple: this is not just “another Candida”. It is a clinical, laboratory and infection prevention problem at the same time.
Key characteristics that need to be remembered
Morphology and growth
On microscopy, it appears as an oval to elongated budding yeast. It does not usually form germ tubes, which helps separate it from Candida albicans in basic teaching terms, although germ tube testing is not enough for definitive identification.
On routine fungal media, colonies are typically smooth and cream to pale coloured. Chromogenic media may give variable appearances depending on the product used, so colour alone should not be used for species-level identification.
Useful laboratory features include:
Growth at higher temperatures, including around 40 to 42 °C
Salt tolerance compared with many other yeasts
Ability to form biofilms on surfaces and devices
Lack of reliable identification by some older commercial systems
The organism has several major genetic clades. These have been linked to different geographical regions and have distinct resistance profiles. In practice, the clade matters most for epidemiology and outbreak investigation, often through reference laboratory typing or whole-genome sequencing.
Transmission
Transmission is mainly healthcare associated. The organism colonises skin, especially warm and moist sites such as the axilla and groin. It may also contaminate the patient environment.
Common routes include:
Direct contact with colonised or infected patients
Indirect transmission via shared equipment
Contaminated surfaces in bed spaces or side rooms
Possible spread during prolonged admissions in intensive care or high-dependency areas
It can survive on surfaces for prolonged periods compared with many other yeasts. This explains why environmental cleaning, equipment management and screening of contacts become central to control.
Colonisation can persist. A patient may remain colonised after the acute infection has resolved, and readmission can restart transmission if prior status is missed.
Resistance
Resistance is a major reason the organism receives disproportionate attention. Most isolates are resistant to fluconazole or have high fluconazole MICs. Amphotericin B susceptibility is variable. Echinocandin resistance is less common but clinically serious, especially because echinocandins are preferred for initial therapy.
Mechanisms include alterations in antifungal targets and pathways, such as changes affecting azole susceptibility and mutations associated with echinocandin resistance. Laboratory interpretation should follow local and reference laboratory advice because species-specific clinical breakpoints are not as straightforward as for common Candida species.
For the exam, avoid saying “all isolates are multidrug resistant”. A safer answer is:
Many isolates have reduced susceptibility or resistance to one or more antifungal classes, especially fluconazole, and susceptibility testing is essential for invasive infection.
Clinical implications and at-risk populations
The organism can cause a spectrum from colonisation to invasive disease. Part 2 scenarios often test whether colonisation is recognised as an infection control problem even when no antifungal treatment is required.
Infections it causes
Clinically important infections include:
Candidaemia
Central venous catheter-associated bloodstream infection
Intra-abdominal infection
Wound infection
Urinary tract infection, particularly catheter-associated cases
Otitis and other superficial infections, less commonly tested in acute scenarios
Interpretation depends on the specimen. Isolation from blood or another sterile site is clinically significant. Isolation from urine, respiratory samples or skin screening swabs needs clinical context. Respiratory isolation often reflects colonisation rather than invasive pulmonary candidiasis.
In a written exam, a good answer for candidaemia should include:
Prompt antifungal therapy
Repeat blood cultures until clearance
Source control, including line removal where feasible
Echocardiography and eye review where clinically indicated or according to local candidaemia pathways
Species identification and susceptibility testing
Infection prevention precautions if this organism is suspected or confirmed
At-risk populations
Risk factors overlap with invasive candidiasis generally, but healthcare exposure is especially important.
High-risk groups include:
Intensive care and high-dependency patients
Patients with central venous catheters
Those receiving broad-spectrum antibiotics
Patients after major surgery
People receiving parenteral nutrition
Patients with renal replacement therapy
Immunocompromised patients
Those with prolonged or repeated healthcare admissions
Residents transferred from facilities with known transmission
In exam answers, link risk factors to mechanism. For example, central lines create a route for bloodstream infection, broad-spectrum antibiotics reduce competing flora, and prolonged bed-space exposure increases opportunities for acquisition.
Diagnostic methods and laboratory identification
A strong laboratory answer should not stop at “send MALDI-TOF”. It should describe when to suspect the organism, how to confirm it, and what to do next.
When to suspect it
Suspicion should rise when a yeast isolate is recovered from a high-risk patient or outbreak setting, especially if the initial identification is unusual.
Possible warning signs include:
Yeast isolated from blood in an ICU patient with prolonged admission
Identification as a member of the Candida haemulonii complex
Repeated recovery of uncommon Candida species from several patients on the same ward
A yeast isolate with high fluconazole MIC
A transfer from a hospital or care facility with known transmission
Older systems may misidentify the organism as other yeasts. Examples reported in practice include Candida haemulonii, Candida duobushaemulonii, Candida famata, Candida sake, Candida lusitaniae, Saccharomyces cerevisiae or Rhodotorula glutinis, depending on the platform and database.
The exact misidentification pattern is system dependent, so an exam answer should avoid overclaiming. The key is to state that unusual identifications require confirmation using an updated method.
Culture and screening specimens
For diagnostic infection work-up, send specimens according to the syndrome:
Blood cultures for suspected candidaemia
Line tip culture if a catheter is removed, interpreted with caution
Sterile site samples where relevant
Urine, wound or drain samples only when clinically indicated
For screening, many protocols use composite swabs from the axilla and groin because skin colonisation is common at these sites. Nose, throat, urine, rectal or wound swabs may be added depending on local guidance and the outbreak setting.
Selective or chromogenic media can support screening. Some laboratories use enrichment broths, high-salt conditions or higher incubation temperatures to improve recovery. A positive screening culture still needs reliable species identification.
Identification methods
Reliable methods include:
Method | Exam relevance | Main limitation |
MALDI-TOF MS with an updated database | Fast species-level identification in many modern laboratories | Older databases may fail or misidentify |
Sequencing of ITS or D1/D2 regions | Reference-level confirmation | Slower and usually not first-line in routine labs |
Molecular PCR assays | Useful for rapid detection or outbreak screening where available | Availability varies by laboratory |
Updated commercial identification systems | May be acceptable if validated locally | Performance depends on version and database |
Reference laboratory confirmation | Important for unusual isolates, resistance or outbreaks | Turnaround may affect immediate decisions |
MALDI-TOF is often the expected answer, but only if the database includes the species. For FRCPath, saying “MALDI-TOF, ensuring the database is current, with reference laboratory confirmation if needed” is stronger than simply naming the technology.
Susceptibility testing
Antifungal susceptibility testing should be performed for invasive isolates and outbreak-relevant isolates. Agents usually include:
Fluconazole
Voriconazole or other azoles where locally indicated
Anidulafungin, micafungin or caspofungin
Amphotericin B
Interpretation can be complex because established clinical breakpoints may be limited or differ between systems. Laboratories may report MICs with expert interpretation, often with reference laboratory input.
If echinocandin resistance is suspected, repeat testing and resistance mechanism analysis may be needed. A rising echinocandin MIC during therapy is clinically significant and should prompt urgent specialist review.
Immediate reporting
Do not wait for every result before informing clinical and infection prevention teams. A good exam phrase is:
A suspected or confirmed isolate from a high-risk setting should trigger early communication with the clinical team, infection prevention and the reference laboratory.
That sentence shows safe practice.
Treatment options and therapeutic challenges
Treatment depends on whether the patient is colonised or infected. This distinction is often tested.
Colonisation does not require antifungal treatment. It does require infection prevention measures. Treating colonisation risks toxicity, resistance and false reassurance.
For invasive disease, an echinocandin is generally recommended as initial therapy in adults, pending susceptibility results and clinical response. Options include anidulafungin, micafungin and caspofungin, depending on local formulary.
Practical treatment principles
For candidaemia or invasive infection:
Start an echinocandin promptly
Remove or replace central venous catheters where feasible
Repeat blood cultures to document clearance
Seek source control, such as drainage of collections
Review susceptibility results with microbiology or infectious diseases specialists
Consider step-down therapy only if the isolate is susceptible, the patient is stable, and blood cultures have cleared
Treat for an appropriate duration, commonly at least 14 days after bloodstream clearance and symptom resolution for uncomplicated candidaemia, following local guidance
If there is clinical failure or resistance, options may include liposomal amphotericin B or combination treatment under specialist advice. Flucytosine may have a role in selected combinations, but toxicity and susceptibility need attention.
For neonates and children, treatment choices and dosing differ, so specialist paediatric advice is needed.
Why treatment is difficult
Therapeutic challenges include:
Baseline fluconazole resistance in many isolates
Emerging echinocandin resistance during treatment
Biofilm-associated infection on lines and devices
Severe underlying illness in affected patients
Limited high-quality trial evidence compared with common Candida infections
The clinical exam angle is not to memorise every dosing schedule. It is to show safe priorities: start appropriate therapy, remove infected devices if possible, test susceptibility, monitor clearance and escalate if response is poor.
Infection prevention and control in routine care
This is where many candidates lose marks by giving generic Candida advice. The organism needs a contact transmission approach.
Core measures include:
Place the patient in a single room, ideally with en-suite facilities
Use contact precautions according to local policy
Ensure strict hand hygiene
Use dedicated or single-patient equipment where possible
Clean shared equipment thoroughly after use
Flag the patient record for future admissions
Inform receiving units before transfer
Screen contacts based on local risk assessment
Clean the environment with products active against yeasts and approved locally
Alcohol-based hand rub is generally suitable for routine hand hygiene when hands are not visibly soiled. Soap and water is needed when hands are visibly dirty and in line with local policy. The more common failure is not the product but missed moments, poor equipment cleaning and weak communication at transfer.
Environmental cleaning deserves specific mention. Bed rails, clinical equipment, mattresses, hoists, commodes, blood pressure cuffs and temperature probes can become part of transmission if not managed properly. Many outbreak reports have highlighted the patient environment and reusable equipment as key control points.
Patient movement should be limited where possible, but necessary investigations and treatment must still happen. Infection prevention should reduce risk without denying care.
Outbreak scenarios and management
A common Part 2 scenario is a cluster of yeast bloodstream infections or colonised screening swabs in an ICU. The examiner is looking for structured leadership, not panic.
Recognise the outbreak
An outbreak may be suspected when:
Two or more linked cases occur in time and place
A single confirmed case appears in a high-risk unit with possible transmission
Screening identifies unexpected colonisation in contacts
A rare yeast is repeatedly isolated from patients in the same area
Start with a working case definition. For example:
Confirmed case
Laboratory-confirmed organism from any clinical or screening specimen
Probable case
Epidemiological link with compatible preliminary identification
Colonised case
Positive screening swab without evidence of infection
Infected case
Clinical disease with compatible specimen, such as bloodstream infection
Form an incident team
The incident team should include microbiology, infection prevention, the clinical unit, nursing leadership, antimicrobial pharmacy, estates or cleaning services, laboratory management and public health or regional experts where required.
First actions should be practical:
Create a line list of cases and contacts
Map bed spaces and patient movements
Review admissions, transfers and discharges
Check laboratory identification methods
Confirm isolates through a reliable platform or reference laboratory
Perform antifungal susceptibility testing
Start contact screening
Reinforce cleaning and equipment decontamination
Review compliance with hand hygiene and PPE
Communicate with receiving hospitals and care facilities
A line list is not just administrative. It helps generate hypotheses. If several cases used the same mobile ultrasound probe or occupied the same bed space, the investigation changes.
Use epidemiology and typing wisely
Whole-genome sequencing can help show whether isolates are closely related. It can support or refute suspected transmission. It does not replace basic epidemiology.
A strong exam answer says that typing should be interpreted alongside dates, bed movements, shared staff, shared equipment and environmental findings.
Manage the environment
Environmental sampling is not always needed for every isolated case, but it can help during persistent transmission. Samples may target high-touch surfaces, reusable equipment and wet areas depending on the suspected route.
Cleaning interventions may include:
Enhanced daily cleaning
Terminal cleaning after discharge
Review of disinfectant choice and contact time
Replacement or deep cleaning of contaminated equipment
Removal of difficult-to-clean items
Audit with feedback
Avoid claiming that one technology alone will end an outbreak. Hydrogen peroxide vapour or ultraviolet decontamination may support terminal cleaning in some settings, but manual cleaning and equipment control remain essential.
Decide when control has been achieved
Control depends on no new cases after appropriate screening and observation, improved compliance, and confidence that reservoirs have been addressed. The required period varies with local guidance and the setting.
For a viva, finish with communication. The patient should be informed, receiving facilities should be alerted, and future readmissions should trigger precautions from the front door.
Exam tips for FRCPath Medical Microbiology Part 2
This topic can appear in the viva, data interpretation, bench-style questions, infection control stations or a written outbreak scenario. The best answers are structured and operational.
Common questions and high-yield answers
Question style | What the examiner wants |
“A blood culture grows an unusual Candida from an ICU patient. What do you do?” | Confirm identification, start appropriate treatment, alert infection prevention, perform susceptibility testing, assess source control |
“Why is this organism important?” | Resistance, misidentification, persistence, healthcare transmission, outbreaks |
“How do you identify it?” | MALDI-TOF with updated database, sequencing or molecular confirmation, reference lab if needed |
“How is colonisation managed?” | No antifungal therapy, contact precautions, screening, environmental cleaning, flagging |
“How would you manage an ICU outbreak?” | Case definition, incident team, line list, screening, cleaning, equipment review, typing, communication |
A model viva answer
If asked to manage a suspected bloodstream isolate, a concise answer could be:
“The isolate is clinically significant if from blood. I would inform the clinical team urgently, recommend an echinocandin pending susceptibility, repeat blood cultures and review line removal and source control. I would confirm the species using MALDI-TOF with an updated database or reference laboratory testing, request susceptibility testing, and alert infection prevention because of the risk of healthcare transmission. I would screen contacts according to local guidance, place the patient in a single room with contact precautions, review environmental cleaning and ensure transfer communication.”
That answer covers clinical care, lab confirmation and infection control in under a minute.
Words and phrases that score well
Use precise terms:
“Colonisation versus infection”
“Updated MALDI-TOF database”
“Reference laboratory confirmation”
“Echinocandin first-line for invasive disease”
“Antifungal susceptibility testing”
“Axilla and groin screening swabs”
“Contact precautions”
“Dedicated equipment”
“Line list and bed-space mapping”
“Whole-genome sequencing interpreted with epidemiology”
Common pitfalls
Avoid these mistakes:
Treating colonisation with antifungals
Assuming all Candida species behave like endogenous flora
Relying on chromogenic colour alone
Forgetting to alert infection prevention
Giving fluconazole as default empirical therapy
Ignoring reusable equipment in an outbreak
Failing to communicate colonisation status on transfer
Overstating certainty from typing without epidemiological context
Study strategy
Build a one-page revision sheet with five boxes:
Why it matters
Identification
Resistance and treatment
Infection prevention
Outbreak management
Then practise three short answers:
A two-minute viva response for a blood culture isolate
A five-minute outbreak plan for an ICU cluster
A bench answer for an unusual yeast misidentified by a commercial system
Use UKHSA, local infection prevention guidance, EUCAST or CLSI susceptibility principles, and reference laboratory advice as the framework. The exam is unlikely to reward obscure molecular detail if the practical response is unsafe.
For written practice, force each answer to include both patient-level and unit-level actions. This mirrors real consultant work and fits the Part 2 standard.
Frequently asked questions
Is this organism always pathogenic?
No. It may represent colonisation, especially from skin screening swabs, urine or non-sterile sites. Bloodstream or sterile site isolation is clinically significant and needs urgent treatment and infection control action.
What is the first-line treatment for invasive infection?
An echinocandin is generally used first-line in adults while susceptibility and clinical response are assessed. Treatment should include source control and repeat blood cultures.
Should colonised patients receive antifungal treatment?
No. Colonisation alone is not treated with antifungals. It is managed with infection prevention measures, screening decisions, environmental cleaning and clear communication during transfers.
Why can identification be difficult?
Some older commercial databases do not reliably include or separate this organism from related yeasts. MALDI-TOF with an updated database, sequencing, molecular assays or reference laboratory confirmation may be needed.
What is the most exam-relevant outbreak action?
Start with a case definition, line list, contact screening, isolation precautions, cleaning review and reliable laboratory confirmation. Then use typing and epidemiology together to understand transmission.
Final takeaway
For FRCPath Part 2, the safest way to approach this topic is to treat it as a three-part problem. The laboratory must identify the yeast accurately. The clinical team must treat invasive infection promptly and check susceptibility. The infection prevention team must prevent spread, even when the patient is only colonised.
A high-scoring answer is not a list of facts. It is a clear plan that joins microbiology, antifungal therapy and outbreak control into one response.
Comments